Text Size

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2008 by Gachon University Gil Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Gachon University Gil Medical Center
ClinicalTrials.gov Identifier:
NCT00319800
First received: April 28, 2006
Last updated: March 10, 2008
Last verified: March 2008
History of Changes
  Purpose

To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable clinical parameter treated with irinotecan.


Condition Intervention Phase
Non-Small Cell Lung Cancer
 Drug: Gefitinib
Drug: Irinotecan
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Gachon University Gil Medical Center:

Primary Outcome Measures:
  • Objective response rate
  • Progression-free survival

Secondary Outcome Measures:
  • Overall survival
  • Toxicity

Estimated Enrollment: 50
Study Start Date: February 2006
Estimated Study Completion Date: March 2007
Detailed Description:

It has been suggested that some clinical parameters, including women, no smoking history and a histologic diagnosis of adenocarcinoma, are associated with favorable outcomes of gefitinib therapy. We will conduct a phase II study in docetaxel pretreated advanced NSCLC patients treated with gefitinib or irinotecan according to these clinical parameters in order to determine whether in patients with favorable clinical parameter(s) gefitinib will produce difference outcomes from patients without favorable clinical parameter treated with irinotecan.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aged 75 years or less
  • histologically or cytologically confirmed non-small cell lung cancer
  • advanced, metastatic or recurrent
  • ECOG performance status 0 to 2
  • one prior palliative chemotherapy including docetaxel
  • measurable or evaluable indicator lesion(s)
  • normal marrow, hepatic and renal function
  • provision of written informed consent

Exclusion Criteria:

  • active infection and/or severe comorbidities
  • pregnant or breastfed women
  • active CNS metastasis
  • active bleeding in GI tract or elsewhere
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00319800

Locations
Korea, Republic of
Gachon University Gil Medical Center
Incheon, Korea, Republic of, 405 760
Sponsors and Collaborators
Gachon University Gil Medical Center
Investigators
Principal Investigator: Se Hoon Park, MD Gachon University Gil Medical Center, Incheon, Korea
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00319800     History of Changes
Other Study ID Numbers: GMO-LU-62
Study First Received: April 28, 2006
Last Updated: March 10, 2008
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Irinotecan
Docetaxel
 Gefitinib
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013